

Cohort study to measure COVID-19 vaccine effectiveness among health workers in the WHO European Region

Guidance Document

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition: Cohort study to measure COVID-19 vaccine effectiveness among health workers in WHO European Region: Guidance Document. Copenhagen: WHO Regional Office for Europe; 2021”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. (<http://www.wipo.int/amc/en/mediation/rules/>)

Suggested citation. Cohort study to measure COVID-19 vaccine effectiveness among health workers in WHO European Region: Guidance Document. Copenhagen: WHO Regional Office for Europe; 2021. Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Contents

| | |
|--|-----------|
| Acknowledgements | iv |
| Abbreviations..... | iv |
| Executive Summary | v |
| 1. Introduction..... | 1 |
| 2. Objectives..... | 1 |
| 2.1. General objective..... | 1 |
| 2.2. Secondary objectives | 2 |
| 3. Methods..... | 3 |
| 3.1. Study setting..... | 3 |
| 3.2. Study design | 3 |
| 3.3. Study population | 3 |
| 3.4. Inclusion Criteria..... | 3 |
| 3.5. Exclusion Criteria | 3 |
| 3.6. Study period and recruitment | 3 |
| 3.7. Exposure..... | 4 |
| 3.8. Definitions of outcomes | 4 |
| 3.9. Minimum variables to be collected from participants | 5 |
| 3.10. Sample size..... | 5 |
| 3.11. Study procedures..... | 7 |
| 3.11.1. T0. Study Preparation | 7 |
| 3.11.2. T1 Enrolment: questionnaire, respiratory sample, and serology sample | 7 |
| 3.12. Active follow-up | 8 |
| 3.13. Data collection and Data sources..... | 10 |
| 3.13.1. Data sources | 11 |
| 3.13.2. Data Management and ensuring Data Confidentiality | 12 |
| 3.13.3. Secondary Studies | 12 |
| 4. Laboratory Methods | 12 |
| 4.1. Specimen collection | 12 |
| 4.2. Specimen storage, shipment and transport..... | 12 |
| 5. Analysis Plan | 14 |
| 5.1. Participation | 14 |
| 5.2. Baseline characteristics | 14 |
| 5.3. Vaccine effectiveness | 14 |
| 5.4. Controlling for clustering by health facility..... | 15 |

| | |
|--|----|
| 5.5. Missing data | 15 |
| 5.6. Secondary Analyses | 15 |
| 5.7. Definitions used for secondary analyses measuring VE by previous SARS-CoV-2 infection | 17 |
| 5.8. Sensitivity analyses | 17 |
| 5.9. Additional analysis: test-negative design | 17 |
| 6. <i>Limitations</i> | 18 |
| 7. <i>Ethical considerations</i> | 18 |
| 8. <i>Data Governance</i> | 19 |
| 9. <i>Prevention of SARS-CoV-2 infection in investigation personnel</i> | 19 |
| 10. <i>Risks and benefits for subjects</i> | 20 |
| 11. <i>Dissemination of results</i> | 20 |
| <i>References</i> | 21 |
| <i>Annex 1: Questionnaires</i> | 22 |
| <i>Annex 2: Example of variables, definitions and coding of study data</i> | 41 |
| <i>Annex 3: Informed consent form</i> | 60 |

Acknowledgements

The WHO Regional Office for Europe led the development of this document with Marta Valenciano (Epiconcept), Mark Katz, Pernille Jorgensen, and Richard Pebody (WHO Regional Office for Europe). The WHO Regional Office for Europe convened an ad-hoc expert review committee that provided strategic direction and direct inputs into the protocol. The WHO Regional Office for Europe would like to thank the following members of the review committee (in alphabetical order):

1. Nick Andrews, Public Health England, United Kingdom
2. Melissa Arvay, US Centers for Disease Control and Prevention, Atlanta, GA, USA
3. Sabrina Bacci, European Centre for Disease Prevention and Control, Stockholm, Sweden
4. Ed Belongia, Marshfield Clinic, Wisconsin, USA
5. Alessandro Cassini, World Health Organization, HQ, Geneva, Switzerland
6. Ben Cowling, Hong Kong School of Public Health, Hong Kong
7. Daniel Feikin, World Health Organization, HQ, Geneva, Switzerland
8. Wiebke Hellenbrand, Robert Koch Institute, Germany
9. Kari Johansen, European Centre for Disease Prevention and Control, Stockholm, Sweden
10. Esther Kissling, Epiconcept, Paris, France
11. Arnold Monto, University of Michigan School of Public Health, Michigan, USA
12. Alain Moren, Epiconcept, Paris, France
13. Francisco Nogareda, Pan American Health Organization, Washington DC, USA
14. Hanna Nohynek, THL, Helsinki, Finland
15. Pasi Penttinen, European Centre for Disease Prevention and Control, Stockholm, Sweden
16. Sheena Sullivan, Doherty Institute, Melbourne, Australia
17. Angie Rose, Epiconcept, Paris, France
18. Marc-Alain Widdowson, Institute of Tropical Medicine, Antwerp, Belgium

This publication has been supported by WHO Unity Studies, a global sero-epidemiological standardization initiative.

Abbreviations

| | |
|------------|---|
| COVID-19 | Coronavirus disease 2019 |
| HW | Health worker |
| IPC | Infection prevention and control |
| SARS-CoV-2 | Severe acute respiratory syndrome coronavirus 2 |
| OR | Odds ratio |
| PCR | Polymerase chain reaction |
| PPE | Personal protective equipment |
| RR | Rate Ratio |
| WHO | World Health Organization |

Executive Summary

Many critical questions remain about the effectiveness of COVID-19 vaccines in real-world settings. These questions can only be answered in post-introduction vaccine effectiveness studies.

This guidance document outlines the methods of a prospective one-year cohort study of hospital-based healthcare workers (HWs) to evaluate the effectiveness of COVID-19 vaccine in preventing laboratory-confirmed SARS-CoV-2 infection. HWs should be enrolled ideally prior to or simultaneous with the implementation of the COVID-19 vaccination campaign, after the study protocol is approved by the local ethical review committee. All HWs eligible to be vaccinated with COVID-19 vaccine can be enrolled in the study, including those who intend to get vaccinated, those who don't plan on getting vaccinated, and those who are not sure whether or not they will be vaccinated.

At enrolment, study participants should complete a baseline enrolment survey about demographics, clinical comorbidities, and work- and community-related behaviours related to infection risk. In addition, a baseline serology and a respiratory swab should be collected from participants at enrolment.

During the course of the study, participants should be actively followed for suspected COVID-19 infection. Symptomatic participants who meet a suspected case definition should provide a respiratory sample, by self-swab (following training) or collected by trained HW, which should be tested for SARS-CoV-2 by RT-PCR.

In addition, during the course of the study, as resources permit, participants should be asked to provide a respiratory sample, weekly, regardless of their symptoms, in order to evaluate asymptomatic infection. Samples should be tested by RT-PCR for SARS-CoV-2.

Finally, during the course of the study, serology should be collected periodically from participants. At a minimum serology should be tested for antibodies to SARS-CoV-2 by tests that can distinguish between vaccine-induced antibodies and antibodies that result from natural infection. In addition, if resources allow, sera can undergo additional laboratory testing for correlates of disease protection, and additional blood can also be collected and tested for markers of cell-mediated immunity.

Vaccine effectiveness should be analysed as described in the analysis section below. In addition to the final analysis at the end of the one-year period, interim analyses at different points during the study can be undertaken.

1. Introduction

In late 2019 a novel severe acute respiratory syndrome – coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), emerged. On 11 March 2020, the World Health Organization declared COVID-19 a pandemic. As of January 9, 2020, 28,320,275 million cases and 616,465 deaths had been reported to the World Health Organization (WHO) Regional Office for Europe (1).

International collaborative efforts have accelerated the development of COVID-19 vaccines. As of January 9, 2020, 63 candidate vaccines were in clinical development, 173 were in preclinical development (2).

Health workers (HW) at a higher risk of infection. In addition, HW can transmit the infection to susceptible patients at high risk of severe COVID-19. The WHO SAGE roadmap for prioritizing uses of COVID-19 vaccines in the context of limited vaccine supply includes HW as a priority group for vaccination. This recommendation was further supported by the European Technical Advisory Group on immunizations in November 2020 (3).

Evaluating the real-world COVID-19 vaccine performance is critical for understanding the risks and benefits of vaccination programs. Many factors impact real-world vaccine effectiveness (VE), including vaccine transportation and storage and how patients are vaccinated. In addition, the people who get the vaccine in clinical trials are often young and healthy, and therefore different from those who will receive vaccines in the real world (4).

Real-world VE studies can also answer questions about effectiveness by age-group and risk factors, duration of vaccine protection, protection against transmission, relative effectiveness of different vaccines, relative effectiveness of one dose vs. two doses, and effectiveness of the vaccine against new strains of SARS-CoV-2.

This document outlines the methods of a prospective cohort study to evaluate the effectiveness of the COVID-19 vaccine in the health workers (HWs), with a focus on hospital-based HWs. This document is intended to be used as a guidance document to support countries and institutions that are interested in conducting research on COVID-19 vaccine effectiveness in health workers. It outlines an approach to post-introduction COVID-19 vaccine effectiveness evaluation in HWs that complements existing WHO Unity Studies, which focus on sero-epidemiological investigations (5). Research should be conducted only after site-specific protocols are developed and approved by the relevant local ethical review committee(s).

2. Objectives

2.1. General objective

To measure product-specific COVID-19 vaccine effectiveness (VE) amongst hospital health workers eligible for vaccination against any laboratory-confirmed SARS-CoV-2 infection

2.2. Secondary objectives

Depending on sample size, to measure COVID-19 VE:

- against symptomatic laboratory-confirmed COVID-19 infection
- against asymptomatic laboratory-confirmed COVID-19 infection
- against severe laboratory-confirmed COVID-19 infection
- by time since vaccination
- by different age groups
- by different high-risk comorbidities
- previous SARS-CoV-2 infection
- by HW occupation and/or ward
- patient-facing vs. non-patient-facing HWs
- in individuals who have been partially vaccinated (one dose for most COVID-19 vaccines) compared to those who are fully vaccinated (two doses for most COVID-19 vaccines)
- against SARS-CoV-2 variant strains

Table 1. Secondary Objectives

| Secondary Objective | Description/Notes |
|--|---|
| 1. What is VE against symptomatic laboratory-confirmed COVID-19 infection | Outcome is symptomatic infection defined by accepted case definition for suspected COVID-19 |
| 2. What is VE against asymptomatic laboratory-confirmed COVID-19 infection | No symptoms are reported in relation to positive SARS-CoV-2 infection |
| 3. What is the VE against severe laboratory-confirmed COVID-19 infection | Severe infection can be defined by WHO case definition. Hospitalization can also be considered as a proxy |
| 4. What is the duration of protection conferred by the vaccine | Time since vaccination |
| 5. What is the VE in different age groups | Age group categories can be determined in relation to number and age distribution of participants |
| 6. What is the VE in persons with different high-risk comorbidities | High-risk comorbidities can be defined according to known risk factors for severe COVID-19 disease |
| 7. What is the VE in persons with reports of previous SARS-CoV-2 infection | Previous infection can be defined by prior PCR-confirmed infection or serology attesting to prior infection |
| 8. What is the VE by health worker occupation | The analysis can also relate to hospital ward rather than profession |
| 9. What is the VE in patient-facing health workers | Patient-facing status should be determined through |

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24757

